摘要
目的:分析我院儿童慢性乙型肝炎(乙肝)抗病毒药物使用情况,为临床合理用药提供参考。方法:选取2014年5月~2015年7月在我院进行慢性乙肝抗病毒治疗持续时间>1年的患儿,对初始药物选择、开始在我院抗病毒时的年龄分布、超说明书使用情况以及治疗期间HBV-DNA改变情况等进行统计分析。结果:41例儿童慢性乙肝患者抗病毒用药选择中,开始治疗选择拉米夫定的占36.58%,但其中66.67%的患儿1年内调整了抗病毒药物;拉米夫定、阿德福韦酯、恩替卡韦、替比夫定等药品使用中都存在超说明书用药情况。结论:儿童抗病毒用药不宜首选拉米夫定,儿童用药需要进行规范化管理,及时进行相关临床试验以更新说明书关于儿童用药的部分,保证儿童患者的用药安全。
Objective: To investigate the utilization of anti-HBV drugs in children with chronic hepatitis B,in order to guide the clinical rational drug use. Methods: The children were chosen from May 2014 to July 2015 in our hospital,more than one years of continuous treatment. The age distribution of antiviral drugs used in our hospital. The initial drug selection began in our hospital,off-label drug use in children and HBV-DNA changes during the treatment period were analyzed. Results: Among the antiviral treatment for 41 cases children with chronic hepatitis B,the most options for children were lamivudine at first,accounted for 36. 58%. But one year adjustment of antiviral drugs accounted for 66. 67%; The situation exists in the use of ultra manual by lamivudine,adefovir,entecavir and telbivudine. Conclusion: Children with antiviral drugs should not be preferred lamivudine. For the safety use of drugs in children,standardized management was urgently needed,clinical trials of pediatric pharmacology should be done to update the information of drug labels.
出处
《药物流行病学杂志》
CAS
2017年第1期53-55,共3页
Chinese Journal of Pharmacoepidemiology
关键词
儿童
乙型肝炎
慢性
抗病毒药物
合理用药
Children
Hepatitis B
chronic
Antiviral drugs
Rational drug use